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Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation
(HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued
is a subject of debate. Assessments of the risks of transplant-related complications that include infertility
and debilitating graft-versus-host disease and long-term quality of life after successful HCT are difﬁcult to
performwithout prospective trials in transplant and nontransplant cohorts. However, it is possible to assess
the risk of mortality and to compare published rates of survival in individuals with SCD treated and not
treated by HCT. In this brief review, projections about mortality risk based on recent published reports are
reviewed and summarized. The published data show overall survival and event-free survival rates of 95%
and 92%, respectively, in children treated by HLA-identical sibling HCT. The overall survival rates in the
Center for International Blood and Marrow Transplant Research (N ¼ 412) and European Blood and Marrow
Transplant (N ¼ 487) registries were 91% and 95%, respectively. These results provide broad support for the
therapeutic value of HLA-identical sibling HCT for children with SCD and serve as the basis for a strong
recommendation in favor of the option of HCT when a suitable donor is available. The experience of HLA-
identical sibling HCT in adults with SCD is limited but appears to be similar to results in children. These
preliminary observations, however, warrant further investigation.
 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION
Hematopoietic cell transplantation (HCT) for sickle cell
disease (SCD) is curative in most individuals who receive
this treatment, but it is a treatment option that very few
families and patients pursue [1-4]. The principal reasonwhydgments on page 210.
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.cho.org (M.C. Walters).
15.10.017
ty for Blood and Marrow Transplantation. Publi
g/licenses/by-nc-nd/4.0/).so few transplants are performed is that most affected
people lack a suitable donor. Even so, it is estimated that 18%
of affected individuals will have an HLA-identical (HLA-ID)
sibling donor [5]. Yet, far less than 1% of the SCD population
in the United States has received a transplant. Many barriers
to transplant exist, and these are detailed in other reports
[6-8]. A key barrier is a prevailing assumption that HCT
is risky and carries a mortality rate that exceeds mortality
experienced with a supportive care approach. In addition,
there are risks of infertility and of graft-versus-host disease
(GVHD), which can cause a chronic debilitating disorder.shed by Elsevier Inc. This is an open access article under the CC BY-NC-ND
Table 1
Indications for HCT in Children with SCD (HbSS or HbS b-thalassemia)
One or more of the following complications:
Stroke or central nervous system event lasting longer than 24 hours
Impaired neuropsychological function with abnormal cerebral magnetic
resonance imaging and angiography
Recurrent acute chest syndrome
Stage I or II sickle lung disease (deﬁned in [14])
Recurrent vaso-occlusive painful episodes or recurrent priapism
Sickle nephropathy (glomerular ﬁltration rate 30%-50% of predicted
normal)
M.C. Walters et al. / Biol Blood Marrow Transplant 22 (2016) 207e211208In this brief review the basis for assumptions about mor-
tality risk is examined in an update of the contemporary
experience of HLA-ID sibling HCT for SCD.
An important beneﬁt of successful HCT is the elimi-
nation of sickle erythropoiesis, thereby signiﬁcantly
reducing, or in most instances, ending the risk of sickle-
related complications [1,9,10]. Thus, most agree that qual-
ity of life after successful HCT should be very much
improved compared with that in individuals who continue
to live with SCD. These comparisons about protection from
sickle-related damage are difﬁcult because prospective
comparisons between groups of subjects treated by HCT and
by supportive care have never been conducted. Thus, most
analyses rely on comparisons with historical control sub-
jects, which weakens their impact. In addition, some re-
cipients have experienced events soon after HCT, such as
pain, intracranial hemorrhage, and infection. Thus, protec-
tion is not universal in those who survive with engraftment
of donor cells, although these events eventually resolve. For
these reasons the beneﬁt of HCT with regard to symptom
abatement and organ function is not the focus of this re-
view. However, the importance of conducting studies that
systematically monitor prospective outcomes in comparison
cohorts that might establish unequivocal indications for
HCT cannot be overstated.HCT IN CHILDREN WITH SCD
In developing eligibility criteria for HCT in early studies,
investigators selected clinical features of SCD that carry a
high burden of ongoing supportive care with a risk of cu-
mulative organ injury and an association with early mor-
tality [11]. In childhood, supportive care delivered at
comprehensive sickle cell centers is currently associated
with excellent survival to adulthood, with a risk of mortality
before age 18 that ranges from 1% to 2% by age 20 in the East
London Cohort to 6.1% in the Dallas Newborn Cohort [12,13].
Thus, transplantation studies in childhood focused initially
on minimizing the risks of early transplant-related death
and of sickle-related clinical complications after successful
transplantation. Currently, HCT in children with SCD is
typically restricted to those with a clinical stroke or who
have experienced recurrent vaso-occlusive complications
such as pain and/or acute chest syndrome despite receiving
optimal supportive care. The eligibility criteria used in the
largest pediatric clinical trials completed 10 to 15 years ago
are presented in Table 1. In the current era as the survival
rates in transplant and nontransplant cohorts converge,
restricting HCT solely in children who have had a signiﬁcant
complication such as stroke is no longer appropriate, as
suggested below. A liberalized approach to indications for
HCT would also increase its utilization.TRANSPLANT RESULTS IN CHILDREN: HLA-ID SIBLING
HCT
A compilation of the most recent single-center patient
series in children with SCD treated by HLA-ID sibling HCT is
presented in Table 2. In a series of 40 patients treated in
Rome, Italy, the rates of overall survival and event-free sur-
vival (EFS) were both 91% after an HLA-ID sibling bone
marrow transplantation (BMT) with a conventional prepar-
ative regimen of busulfan (BU)/cyclophosphamide/horse
antithymocyte globulin (ATG) with or without ﬂudarabine
(Flu) [15]. In a series from Belgium, 37 of 38 children treated
since 1995, who also received hydroxyurea (HU) well before
HCT, survived free of SCD with an 8-year estimate of EFS of
97.1% [16]. In a series of children treated in New York who
received a combination of BU, Flu, and alemtuzumab (Alem)
before HLA-ID sibling HCT, all 18 children survived free of
SCD after HCT [17]. Another single-center series from Atlanta
observed 24 of 25 patients who were treated by HLA-ID
sibling HCT between 1993 and 2007, after preparation with
BU/cyclophosphamide/horse ATG, who survived free of SCD
[19]. A recent multicenter investigation of 43 children with
SCDwho received Alem/Flu/melphalan before HLA-ID sibling
BMT reported survival and EFS probabilities of 93% and
90.7%, respectively [21]. Finally, the experience from Pavia
was also recently reported inwhich all 30 recipients survived
after HLA-ID HCT after preparation with BU/thiotepa/Flu or
treosulfan/thiotepa/Flu and ATG [20]. Together these com-
bined series include 218 recipients, of whom 208 (95%) sur-
vived after transplantation and 200 (92%) survived free of
SCD. These updated published results strongly suggest that
survival after HCT from an HLA-ID sibling in children with
SCD is not inferior to survival among those treated by stan-
dard supportive care. At last follow-up only 6 survivors (3%)
were receiving immunosuppressive therapy to treat chronic
GVHD.
Similar results have been reported from transplant reg-
istry data where there are approximately 1200 SCD trans-
plant cases from related and alternate donor sources [22].
Among the HLA-ID sibling donor cohorts, the rates of overall
survival in the Center for International Blood and Marrow
Transplant Research (N ¼ 412) and Eurocord/European
Blood and Marrow Transplant (EBMT; N ¼ 487) registries
were 91% and 95%, respectively [22]. In a separate analysis
comparing outcomes in 160 childrenwith SCDwho received
HLA-ID sibling BMT and umbilical cord blood trans-
plantation between 1994 and 2005 in the United States and
Europe, there was no statistically signiﬁcant difference in
overall survival and EFS between these 2 donor sources [23].
Moreover, the combined 6-year disease-free survival rate
was 92%.
These retrospective registry data also were reviewed
critically by an international expert panel on behalf of the
EBMT Inborn Error and EBMT Paediatric Working Parties
[24] and the following recommended for HLA-ID HCT for
children:
 Young patients with symptomatic SCD who have an
HLA-ID sibling donor should be transplanted as early as
possible, preferably at preschool age.
 Unmanipulated BM or umbilical cord blood (whenever
available) from HLA-ID sibling donors are the recom-
mended stem cell source.
However, an alternate view recently expressed by SCD
experts is that additional research is still needed to
Table 2
Clinical Outcome of HLA-ID Sibling HCT for Children with SCD
Center Preparative
Regimen
GVHD
Prophylaxis
n Age
Range
(yr)
Published Outcomes Latest Follow-Up
Follow-Up
(yr)
Death (mo) Complications IST GVHD Donor
Chimerism
Rome
(Lucarelli,
2014) [15]
BU 14 mg/kg,
CY 200 mg/kg,
rATG 10 mg/kg,
Flu 150 mg/m2
CsA, MTX,
pred
40 2-17 1-10 3 (2.5, 6, 15) 3 deaths
from GVHD
1 of 40 17.5% aGVHD,
5% cGVHD
25-100%
Brussels
(Dedeken,
2014) [16]
BU 13-18 mg/kg,
CY 200 mg/kg,
rATG (10-20 mg/kg),
HU
CsA, MTX or
MMF (UCB)
50 1.7-15.3 .4-21.3 2 (6, 78) 4, sepsis, 1 IMI,
seizures 21%,
6, PRES
1 of 50 20.5% aGVHD,
20% cGVHD
15-100%
New York
(Bhatia,
2014) [17]
BU 12.8-16 mg/kg,
Flu 180 mg/m2,
Alem 54 mg/m2
Tacrolimus,
MMF
18 2.3-20.2 .4-7.5 None ICH in 1, PRES
in 1, CMV
react in 4
None 17% aGVHD,
11% cGVHD
Mean 88%
at 1 yr
Mississippi
(Majumdar,
2010) [18]
BU 14 mg/kg,
CY 200 mg/kg,
ATG 90 mg/kg
CsA, Pred 10 2.8-16.3 2.9-9.9 1 1 death from
sepsis, 1 AIHA
1 of 10 40% aGVHD
10% ceGVHD
15-100%
Atlanta
(McPherson,
2011) [19]
BU 14 mg/kg,
CY 200 mg/kg,
ATG 90 mg/kg
CsA, MTX 27 3.3-17.4 .1-10 1 (3) 8 VOD, 16%
seizures, 2 ICH
None 12% aGVHD,
1 death from
cGVHD
62-100%
Pavia
(Strocchio,
2015) [20]
BU 16 mg/kg,
TT 10 mg/kg,
Flu 160 mg/m2
or Treo 14 gm/m2,
TT 10 mg/kg,
Flu 160 mg/m2, ATG
CsA, MTX
or MMF
30 1.7-18.8 .5-14 None Stomatitis (43%),
GI toxicity
(17%); no VOD
None 7% Grades I-II
aGVHD, 7%
cGVHD in BU
group, none
in Treo group
50% (BU)
and 36%
(Treo) at
1 yr
United States
(King, 2015) [21]
Alem 48 mg,
Flu 140-150 mg/m2,
melphalan 140 mg/m2
CsA or
tacrolimus
43 3-20.3 .75-11.83 3 (11, 18, 21) 3 deaths
from GVHD
19% by 1 yr;
9% by 2 yr
23% aGVHD,
13.4% cGVHD
29-100%
IST indicates immunosuppressive therapy; CY, cyclophosphamide; rATG, rabbit ATG; CsA, cyclosporine; MTX, methotrexate; pred, prednisone; aGVHD, acute
GVHD; cGVHD, chronic GVHD;MMF,mycophenolate mofetil; UCB, umbilical cord blood; IMI, invasive mold infection; PRES, posterior reversible encephalopathy
syndrome; ICH, intracranial hemorrhage; CMV, cytomegalovirus; AIHA, autoimmune hemolytic anemia; VOD, veno-occlusive disease; Treo, treosulfan; ceGVHD,
chronic extensive GVHD; TT, thiotepa; GI, gastrointestinal.
Table 3
Indications of HCT in Adult Recipients with SCD
Age, 15-40 yr with SCD and 1 or more of the following
Clinically signiﬁcant neurologic event (stroke) or any neurologic deﬁcit
lasting >24 hr
History of 2 or more episodes of acute chest syndrome in the 2-yr period
preceding HCT despite the institution of supportive care measures (ie,
M.C. Walters et al. / Biol Blood Marrow Transplant 22 (2016) 207e211 209address the potential risks of this therapy, such as failure
of engraftment and chronic GVHD before HCT can be
widely used [25]. The objective of reducing the risk of
HCT in children with SCD has been largely accomplished
when an HLA-ID sibling donor is used, which challenges
this opinion. The 2-year transplant-related mortality risk
after HLA-ID sibling donor HCT appears very similar to the
risk in children with SCD who receive standard supportive
care. This notion is further strengthened by a recent
report that described a cohort of 469 children and adults
with SCD in Belgium in which the 15-year survival rate
after transplantation compared with supportive care was
not signiﬁcantly different (mortality rate of .38 and
.36/100 patient-years, respectively, in supportive care and
transplant groups), although survival was superior in a
group treated by with [26]. Novel methods in preserving
fertility after HCT should hasten a revision of the current
indications for HLA-ID sibling HCT, extending this thera-
peutic option to all children who have a sickle cell anemia
genotype. Oocyte cryopreservation has been reported in a
patient with SCD [27]. Cryopreservation of ovarian tissue
is available as a research procedure, and this tissue might
be used to restore endocrine and reproductive function
after HCT [28].asthma therapy and/or HU)
History of 3 or more severe pain crises per year in the 2-yr period
preceding enrollment despite the institution of supportive care
measures (ie, a pain management pain and/or treatment with HU)
Administration of regular RBC transfusion therapy, deﬁned as
receiving 8 or more transfusions per year for 1 yr to prevent vaso-
occlusive clinical complications (ie, pain, stroke, and acute chest
syndrome)
An echocardiographic ﬁnding of tricuspid valve regurgitant
jet  2.7 m/sELIGIBILITY CRITERIA IN ADULTS WITH SCD
There is limited but growing transplant experience in
adults with SCD. The eligibility criteria used in 2 active trials
are shown in Table 3. There is a potential for a wider
acceptability of HCT in adults with severe SCD for several
reasons. First, unlike the experience in childhood during
which survival to adulthood improved signiﬁcantly after theinstitution of comprehensive care, the mortality rate among
adults has changed very little in the past several decades
[29,30]. Patients with symptomatic SCD who participated in
the Multicenter Study of Hydroxyurea represent a cohort
that mirrors adult patients referred for HCT [31]. The annual
mortality rate in the long-term (17.5 years) follow-up cohort
from the Multicenter Study of Hydroxyurea was 4.4 per 100
person-years. The mortality rate was quite similar across
groups who received HU for<5 years, 5 to<10 years, and 10
to <15 years. After roughly 13 years of continuous HU
treatment, however, the mortality rate declined to 2.5% per
year and 2.25% per year in the groups of patients treated for
the longest periods of time. Another recent report of 534
adults with SCD showed 25% mortality at the end of the 10-
year study. The mortality was even higher among those
Table 4
Recent Results of HLA-Matched HCT in Adults with SCD
Center Preparative Regimen GVHD
Prophylaxis
n Age Range
(yr)
Published Outcomes Latest Follow-Up
Follow-Up
(yr)
Death
(mo)
Complications IST GVHD Donor
Chimerism
NHLBI (Hsieh, 2009,
2014) [9,41]
Alem 1 mg/kg, TBI 300 cGy Sirolimus 30 17-65 1.8-6 1 (ICH)
after GR
GR (n ¼ 4) 11 of 26 None Median
T cell 48%
France (Kuentz,
2011) [40]
BU 14 mg/kg, CY 200 mg/kg,
rATG 10 mg/kg
CsA, MTX 15 16-27.5 1-16.1 1 (ICH) SDH (n ¼ 1),
seizures
d 8 aGVHD,
2 cGVHD
75-100%
NHLBI indicates National Heart, Lung, Blood Institute; TBI, total body irradiation; GR, graft rejection; SDH, subdural hematoma.
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severity score [30]. Thus, if the 2-year mortality probability
after HCT in adults is <20%, it is very likely that trans-
plantation will confer a long-term survival advantage in
adult recipients.
Doppler transthoracic echocardiography has been vali-
dated in several cohorts as a screening tool to identify high-
risk patients for early mortality. In 3 large screening studies
approximately 30% of patients had a tricuspid valve regur-
gitant jet velocity (TRV) > 2.5 m/s and 10% had a
TRV> 3 m/s. In all epidemiologic studies performed to date,
the risk ratio of early death in adults with a TRV > 2.5 m/s
ranged from 9.24- to 15.9-fold [32-34]. More recently, a
larger cohort of 483 patients was screened in the Walk-
PHASST (Walk-Treatment of Pulmonary Hypertension and
Sickle Cell Disease with Sildenaﬁl Therapy) screening study
[35,36]. In this cohort, 67 participants (9.1%) had a
TRV > 3 m/s that was associated with a 2-year mortality of
11.9%. Using a 2-variable positive predictive value assess-
ment of 2-year mortality risk in this same cohort, it was
possible to identify very high-risk patients. Subjects who
had a combination of TRV > 3 m/sec with WBC counts
> 13,500 or chronic transfusion therapy had a 2-year mor-
tality rate that exceeded 20% [37]. Finally, 43 of 240 subjects
from a cohort of adults with SCD died between 2000 and
2005, with a median survival of 40 years [38]. The authors
concluded that HU protected from acute sickle-related
events but not from cardiopulmonary complications,
which were the leading cause of death. Thus, in selected
groups of adults with SCD, even if the 2-year probability of
transplant-related mortality is approximately 20%, survival
in the short term compared with those who lack a donor
might be acceptable.
TRANSPLANT RESULTS IN ADULTS: HLA-ID SIBLING HCT
The possibility of successful HCT in young adults with
SCD was suggested by a report of 15 patients from a French
group and by parallel efforts in thalassemia major in
which myeloablative regimens with reduced toxicity were
developed to lower the risk of transplant-related mortal-
ity [39,40] (Table 4). Although reduced-intensity and
nonmyeloablative conditioning regimens have been suc-
cessful in treating hematologic malignancies where there
are comorbidities, these have been less successful in he-
moglobinopathies [42,43]. However, results of more
recent trials suggest progress that might be extended to
clinical practice. Between 2004 and 2013, 30 patients with
severe disease ages 16 to 65 years were treated with Alem,
total body irradiation (300 cGy), and sirolimus followed by
HLA-ID sibling ﬁlgrastim-mobilized peripheral blood stem
cell transplantation in a single-center trial [9,41]. With a
median follow-up of 3.6 years (range, 1.8 to 6), 87% ofrecipients had long-term engraftment without acute or
chronic GVHD and overall survival was 97%. However, 11 of
26 surviving patients who had mixed donorehost
chimerism were still receiving immunosuppressive ther-
apy at last follow-up because of concerns about late graft
failure. Recently, a multicenter pilot trial of HCT for SCD
reported results in 22 adults with severe SCD treated by
HLA-ID related (n ¼ 17) or unrelated (n ¼ 5) donor HCT
after a myeloablative combination of BU, Flu, and rabbit
ATG. Twenty-one of 22 patients survived after HCT, all
with engraftment of donor cells [44]. Together, these
initial series have generated very good results and if
conﬁrmed in a larger, multicenter investigation of HLA-ID
sibling HCT in adults could support the notion that sur-
vival after transplantation is not inferior to survival in
those not treated by HCT.SUMMARY
Just as reﬁnement in supportive care for SCD has
improved the likelihood of survival to adulthood, results
after HLA-ID sibling HCT have also improved signiﬁcantly in
the past 15 years. In addition, the goal of cure is achieved in
90% or more of transplant recipients. Because there appears
to be very little if any survival disadvantage after HCT
compared with those who receive supportive care, a broad-
ened view about transplant eligibility is warranted [45]. The
role of HCT in adults with symptomatic SCD is less well
deﬁned because of the small number of published reports;
however, projections based on the risk of early mortality in
adults with severe SCD also warrants broader endorsement
of HCT as a therapeutic option, particularly when investi-
gated in National Institutes of Healthefunded prospective
clinical trials.ACKNOWLEDGMENTS
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